Opiant Pharmaceuticals (OPNT) 10-Q2010 Q3 Quarterly report

Filed: 14 Dec 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: addressing, adequate, AG, agent, aggregate, aggregating, aim, alternative, amortized, analyzed, Appln, approach, area, ASC, bankruptcy, basic, beneficially, binge, biopharmaceutical, blind, broaden, build, calculation, cancelled, carryforward, carryover, cease, Celesio, challenging, closing, Codification, collaborate, College, commence, compliant, comply, computed, Cont, contacted, cost, ctive, debt, deliver, delivered, denominator, diluted, dilutive, disorder, dividing, double, effectuated, employee, encountered, evidence, Examiner, exercise, expended, expertise, exploit, extinguishment, FASB, favorable, FDA, FIMEA, FlowsFor, forgave, fully, gain, gene, genetic, government, governmental, identified, III, Imperial, intranasal, investigate, Jan, labor, liability, LLC, London, manufacturer, manufacturing, marker, measure, measured, member, method, naloxone, nasal, NOL, Oct, ongoing, OperationsFor, opioid, option, ordinary, outcome, overweight, ownership, paid, patient, payment, people, pipeline, placebo, point, policy, preliminary, price, primarily, proceeding, product, prospectively, randomized, rate, receivership, recently, recognition, recognize, recruited, reduction, remaining, represent, reserved, respe, response, reverse, royalty, safety, settlement, similar, single, specialist, specialty, spray, statutory, stimuli, strategy, subset, successful, suitable, temporary, trademark, UK, unable, uncertain, unique, vesting, weight, whichever

Removed: behaviour, condensed, consisting, consolidated, continuing, controlling, derive, discovery, drug, eliminated, focusing, innovative, intercompany, interest, interim, necessarily, obesity, opinion, presentation, recommended, recurring, ref, unaudited

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

OPNT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lightlake Therapeutics Inc. (the “Company") for the three month ended October 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Dr. Roger Crystal, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: December 14, 2010 By: /s/ Dr. Roger Crystal

Dr. Roger Crystal

Chief Executive Officer

This certification accompanies each Report pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of ss.18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.